An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

This is an open-label, dose escalation and dose expansion study evaluating the safety, tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD), and antitumor activity of PF-07994525 in participants with R/R MM. The study will consist of 2 parts: Part 1 (Dose Escalation) will consist of PF-07994525 dose escalation to assess the safety, tolerability, and preliminary antitumor activity in participants with R/R MM. In Part 2 (Dose expansion), PF-07994525 may be evaluated in additional participants with R/R MM to further assess safety, PK, PD, and preliminary anti-tumor activity.

NCT Number	NCT07426757
Lead Sponsor	Pfizer
Conditions	Advanced Malignancies, Advanced Cancer
Enrollment	120 participants
Start Date	2026-07-01
Primary Completion	2029-07-10 (estimated)
Study Completion	2030-07-10 (estimated)
Updated on ClinicalTrials.gov	2026-07-22